Mike Novotny is the founder and CEO of Medrio. Mr. Novotny applies 20 years of experience in research and software to his eClinical SaaS vision. Prior to founding Medrio, Mr. Novotny was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA.
Read MoreDavid Mace is the Co-founder & CEO of SwiftScale Biologics, a life sciences startup based in San Francisco, California. SwiftScale Biologics accelerates time to market for protein drugs by turning a labor-intensive drug production scale-up challenge into a computational challenge.
Read MoreDavid Bates is a scientist, inventor, investor, and entrepreneur. He has co-founded several companies including Linus Health and Bode. He is a founding partner of Tamarisc Ventures and serves on the board of several high-growth technology companies. He is on the board of directors of TMCity Foundation and is Strategic Advisor to the Digital Medicine Society.
Read MoreStephan is a Co-Founder and Chief Scientific Officer at Anokion, bringing more than 15 years of research expertise in the fields of immunology, protein engineering, and platform technologies to the company. He earned his B.Sc. in Chemical Engineering from the University of Texas at Austin and a Ph.D. in Bioengineering.
Read MoreRobert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015.
Owen Wallace joined Fulcrum in April 2017. He has more than two decades of experience in drug discovery and development across multiple therapeutic areas, including neuroscience, endocrine, infectious, respiratory and rare diseases.
Dr. Paul K. Wotton is Obsidian’s Chief Executive Officer, bringing significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton most recently served as the Founding President and CEO of Sigilon Therapeutics, Inc.
Read MoreChris is Sr. Vice President, Technical Operations at Blueprint Medicines. He has over 25 years of commercial and clinical manufacturing experience in the biopharmaceutical industry and has been fortunate to help develop and commercialize numerous oncology medicines. He has been in his current role since October 2017.
Read MoreCarl P. Decicco is a biopharmaceutical veteran with over 30+ years of experience in the industry. Over the course of his career, Carl has played a central role in the advancement of more than 200 compounds into clinical trials and the approval of more than 20 drugs across multiple therapeutic areas. He’s authored/Co-Authored more than 100 scientific papers in peer reviewed journals and is listed as an inventor on 26 patents.
Read MoreDr. Florian Wegener is the co-founder and CEO of ZAGENO, an award-winning online marketplace serving the needs of research scientists. He is also a board-certified physician.
In 2015, Florian co-founded ZAGENO Inc. in Boston, MA and Berlin, Germany and has since led its commercialization and go-to-market strategy. He relocated to the Greater Boston region in 2018 to continue ZAGENO’s development – principally its marketing, sales, vendor development, integration, investor’s relations and brand reputation.
Read MoreRaman is the founder and global president of ramarketing - an international design, digital and PR agency that's in the business of helping ambitious contract service companies operating in the global biotech and pharmaceutical outsourcing sector get noticed.
Read MoreIn this episode, guest Kevin Bittorf, founder of the Advancing Drug Development Forum and Dawn Dickerson sat down with host Alok Tayi to discuss trends in modern manufacturing and pharmaceutical environments.
Read MoreJon Hennek co-leads the Systems Innovation Team at Indigo Ag. He co-founded the team—whose mission is to create a vision for what agriculture could look like in the distant future and develop a strategy for the Indigo model to dramatically accelerate its adoption—in 2017 while at Flagship Pioneering.
Read More
